Navigation Links
Metabolex Names Zhao, Martin to Executive Posts
Date:7/7/2008

HAYWARD, Calif., July 7 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has promoted Zuchun 'Spring' Zhao to Vice President of Chemical Sciences, and Robert Martin to Vice President of Project and Portfolio Management.

"These appointments represent a significant development in our company in support of our expanding research and clinical pipeline," said Charles McWherter, Ph.D., Senior Vice President of Research and Preclinical Development. "Spring brings a winning combination of creativity in medicinal chemistry along with strong credentials in all aspects of drug discovery and development." Dr. McWherter continued, "Rob is an exceptional asset to Metabolex. He comes with the focus on execution of a biotech but with the savvy of his formative years in pharmaceutical research. Rob is a real master of integrating portfolio strategy with practical operational alternatives."

Dr. Zhao joined Metabolex in 2000 as the head of chemistry, and was instrumental in building the chemistry department. Over the past eight years, he has served in a variety of operational and leadership roles, most recently leading drug discovery projects from lead identification to clinical trials. Earlier in his career, Dr. Zhao worked at Berlex where he contributed to the advancement of several compounds. Dr. Zhao holds a Ph.D. from the University of California Los Angeles, is an inventor on several patents and has published numerous scientific papers in the field of drug discovery.

Dr. Martin joined Metabolex in 2004 and has served the company in a variety of preclinical development and project management positions, most recently as Senior Director of Portfolio Management. He has played a key role in a number of projects in the Metabolex pipeline. Prior to joining the company, he spent ten years with Roche where in his last position -- in the research strategy group -- he focused on improving the productivity of the global research organization. Dr. Martin holds a Ph.D. from the University of California Davis.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, currently being studied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Appoints Donald Hill as Chief Financial Officer
2. KGI Names Kerry Howell Vice President for Advancement
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
6. CryoLife Names Philip Theodore as Vice President, General Counsel
7. Genstar Names Michael Hurt to Its Strategic Advisory Board
8. PPD Names Daniel Darazsdi as Chief Financial Officer
9. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... time members of the Modular Building Institute (MBI), an international modular trade organization, ... the permanent modular category for the Pagliuca Life Lab at Harvard University. The ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... YORK , March 28, 2017 ... highly volatile and unpredictable sector due to the ... Markets served include medical, agricultural, environmental, and industrial. In ... four stocks: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), OvaScience ... and Ocular Therapeutix Inc. (NASDAQ: OCUL ...
(Date:3/27/2017)... WARREN, N.J. , March 27, 2017 Roka ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Spring 2017 Convention on March ... the New York Marriott Marquis. About Roka ... ...
Breaking Biology Technology:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):